• Something wrong with this record ?

The synthesis and influence of the novel bispyridinium compound LB1 on the effectiveness of the standard antidotal treatment of organophosphorus nerve agent intoxicated mice and some structure-activity considerations

J. Kassa, RE. Ambler, LJ. Brown, J. Cummins, AC. Green, CM. Timperley

. 2025 ; 413 (-) : 111470. [pub] 20250308

Language English Country Ireland

Document type Journal Article

The design of MB327, a bispyridinium compound that ameliorates the nicotinic effects of acute organophosphorus nerve agent (NA) intoxication, followed an observation made by the German pharmacologist Klaus Schoene in the 1970s, who noted therapeutic activity in bispyridinium molecules missing the usual oxime group, CHNOH. Some of these compounds protected mice against soman. One structurally related to obidoxime called HY10 had this action. Its oxime moieties were capped by tert-butyl groups: CH=NOtBu. We modified HY10 by changing the bridge between the pyridinium units from a dimethylene ether to a trimethylene group (CH2OCH2 → CH2CH2CH2) and prepared a novel relative of trimedoxime, called LB1, whose synthesis and stereochemistry are described. Unlike obidoxime or trimedoxime, LB1 because of its capped oxime groups, cannot directly reactivate NA inhibited acetylcholinesterase. Its antidotal activity in mice is now reported. The therapeutic efficacy of LB1, atropine alone, atropine with LB1, atropine with an oxime (HI-6, obidoxime or trimedoxime), and atropine with an oxime and LB1, was studied by determining the LD50 values of the NAs soman, sarin, or tabun in mice treated with these compounds or mixtures. LB1 exceeded MB327 in toxicity and its activity was insufficient for a useful addition to the current standard antidotal treatment (protective ratio data are compared to those of MB327). Although this study produced largely negative biological results, the therapeutically beneficial mechanism of the effective bispyridinium non-oxime analogues is unclear, and has been demonstrated only in vivo. The present study points out directions in structural optimisation unlikely to yield the desired therapeutic outcomes and provides a literature review that could promote creative thinking for the design of widely-desirable non-oxime therapeutics for anticholinesterase inhibitors.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015665
003      
CZ-PrNML
005      
20250731091145.0
007      
ta
008      
250708e20250308ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.cbi.2025.111470 $2 doi
035    __
$a (PubMed)40058717
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Kassa, Jiri $u Department of Toxicology and Military Pharmacy, Military Faculty of Medicine, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic
245    14
$a The synthesis and influence of the novel bispyridinium compound LB1 on the effectiveness of the standard antidotal treatment of organophosphorus nerve agent intoxicated mice and some structure-activity considerations / $c J. Kassa, RE. Ambler, LJ. Brown, J. Cummins, AC. Green, CM. Timperley
520    9_
$a The design of MB327, a bispyridinium compound that ameliorates the nicotinic effects of acute organophosphorus nerve agent (NA) intoxication, followed an observation made by the German pharmacologist Klaus Schoene in the 1970s, who noted therapeutic activity in bispyridinium molecules missing the usual oxime group, CHNOH. Some of these compounds protected mice against soman. One structurally related to obidoxime called HY10 had this action. Its oxime moieties were capped by tert-butyl groups: CH=NOtBu. We modified HY10 by changing the bridge between the pyridinium units from a dimethylene ether to a trimethylene group (CH2OCH2 → CH2CH2CH2) and prepared a novel relative of trimedoxime, called LB1, whose synthesis and stereochemistry are described. Unlike obidoxime or trimedoxime, LB1 because of its capped oxime groups, cannot directly reactivate NA inhibited acetylcholinesterase. Its antidotal activity in mice is now reported. The therapeutic efficacy of LB1, atropine alone, atropine with LB1, atropine with an oxime (HI-6, obidoxime or trimedoxime), and atropine with an oxime and LB1, was studied by determining the LD50 values of the NAs soman, sarin, or tabun in mice treated with these compounds or mixtures. LB1 exceeded MB327 in toxicity and its activity was insufficient for a useful addition to the current standard antidotal treatment (protective ratio data are compared to those of MB327). Although this study produced largely negative biological results, the therapeutically beneficial mechanism of the effective bispyridinium non-oxime analogues is unclear, and has been demonstrated only in vivo. The present study points out directions in structural optimisation unlikely to yield the desired therapeutic outcomes and provides a literature review that could promote creative thinking for the design of widely-desirable non-oxime therapeutics for anticholinesterase inhibitors.
650    _2
$a zvířata $7 D000818
650    12
$a pyridinové sloučeniny $x chemická syntéza $x chemie $x terapeutické užití $x farmakologie $7 D011726
650    _2
$a myši $7 D051379
650    12
$a antidota $x chemická syntéza $x chemie $x farmakologie $x terapeutické užití $7 D000931
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    12
$a nervová bojová látka $x toxicita $7 D000067397
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a soman $x toxicita $7 D012999
650    12
$a organofosforové sloučeniny $x toxicita $7 D009943
650    _2
$a acetylcholinesterasa $x metabolismus $7 D000110
650    _2
$a trimedoxim $x chemie $x chemická syntéza $x farmakologie $x terapeutické užití $7 D014289
650    _2
$a cholinesterasové inhibitory $x toxicita $7 D002800
650    _2
$a oximy $x chemie $7 D010091
650    _2
$a atropin $x terapeutické užití $x farmakologie $7 D001285
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ambler, Rachael E $u Chemical, Biological and Radiological (CBR) Division, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, SP4 0JQ, United Kingdom
700    1_
$a Brown, Lynda J $u Chemical, Biological and Radiological (CBR) Division, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, SP4 0JQ, United Kingdom
700    1_
$a Cummins, Jaime $u Chemical, Biological and Radiological (CBR) Division, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, SP4 0JQ, United Kingdom
700    1_
$a Green, A Christopher $u Chemical, Biological and Radiological (CBR) Division, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, SP4 0JQ, United Kingdom
700    1_
$a Timperley, Christopher M $u Chemical, Biological and Radiological (CBR) Division, Defence Science and Technology Laboratory (Dstl), Porton Down, Salisbury, SP4 0JQ, United Kingdom. Electronic address: cmtimperley@dstl.gov.uk
773    0_
$w MED00002111 $t Chemico-biological interactions $x 1872-7786 $g Roč. 413 (20250308), s. 111470
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40058717 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091140 $b ABA008
999    __
$a ok $b bmc $g 2366490 $s 1252790
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 413 $c - $d 111470 $e 20250308 $i 1872-7786 $m Chemico-biological interactions $n Chem Biol Interact $x MED00002111
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...